ArticleIranian biomedical journal2022
Vaccination in Leishmaniasis: A Review Article.
Article in Iranian biomedical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 20 citations in OpenAlex.
- Role of Microbiome and Bacterial Biofilms in the Pathogenesis of Cutaneous Leishmaniasis.Acta parasitologica · 2026Review
- Peptides as a Therapeutic Alternative Against Leishmaniasis: A Scoping Review.Chemical biology & drug design · 2026Article
- Leishmaniasis vaccine research: current status and new directions.Parasitology · 2026Review
- Effectiveness of harmaline along with meglumine antimoniate onVeterinary research forum : an international quarterly journal · 2026Article
- Climatic, socioeconomic, and migratory factors on the epidemiological dynamics of cutaneous leishmaniasis in Colombia, 2007-2021.PLoS neglected tropical diseases · 2025Article
- Preclinical evaluation of immunogenicity and protective efficacy of a recombinant chimeric protein vaccine against visceral leishmaniasis.Parasitology · 2025Article
- Apyrase Protein (PsSP42) Expression in DNA Construct Transfected COS-7 Cells.Iranian biomedical journal · 2025Article
- CRISPR/Cas9-mediated deletion of a kinetoplast-associated gene attenuates virulence in Leishmania major parasites.Medical microbiology and immunology · 2025Article
- Vaccine Designing Technology against Leishmaniasis: Current Challenges and Implication.Current drug discovery technologies · 2025Review
- Preparation, Characterization, and Leishmanicidal Assessment of Silver- and Dapsone-Loaded Niosomes Co-administration:Advanced pharmaceutical bulletin · 2024Article
- Repurposing of Food and Drug Admnistration (FDA) approved library to identify a potential inhibitor ofHeliyon · 2024Article
- Identification of potential inhibitor against Leishmania donovani mitochondrial DNA primase through in-silico and in vitro drug repurposing approaches.Scientific reports · 2024Article
- Identification of Ochrobactrum as a bacteria with transstadial transmission and potential for application in paratransgenic control of leishmaniasis.Parasitology research · 2024Article
- Memory T cells: promising biomarkers for evaluating protection and vaccine efficacy against leishmaniasis.Frontiers in immunology · 2024Review
- Exploration of Antileishmanial Compounds Derived from Natural Sources.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2024Review
- Detection and counting ofFrontiers in medical technology · 2024Article
- Determinants of Visceral Leishmaniasis in Addis Zemen Health Center, Northwest Ethiopia.Journal of tropical medicine · 2024Article
- Metallic Nanoparticles and Core-Shell Nanosystems in the Treatment, Diagnosis, and Prevention of Parasitic Diseases.Pathogens (Basel, Switzerland) · 2023Review
- A New Strategy for Mapping Epitopes of LACK and PEPCK Proteins ofInternational journal of molecular sciences · 2023Article
- Vaccinomics-based next-generation multi-epitope chimeric vaccine models prediction againstFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is caused by protozoan Leishmania parasites that are transmitted through female sandfly bites. The disease is predominantly endemic to the tropics and semi-tropics and has been reported in more than 98 countries. Due to the side effects of anti-Leishmania drugs and the emergence of drug-resistant isolates, there is currently no encouraging prospect of introducing an effective therapy for the disease. Hence, it seems that the key to disease control management is the introduction of an effective vaccine, particularly against its cutaneous form. Advances in understanding underlying immune mechanisms are feasibale using a variety of candidate antigens, including attenuated live parasites, crude antigens, pure or recombinant Leishmania proteins, Leishmania genes encoding protective proteins, as well as immune system activators from the saliva of parasite vectors. However, there is still no vaccine against different types of human leishmaniasis. In this study, we review the works conducted or being performed in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.